Shelf-stable reagents BIOLYPH enables shelf-stable, rehydration-ready reagents via LyoSpheres and ReActivator delivery systems, presenting a compelling value proposition for diagnostics manufacturers seeking extended shelf life and simplified supply chains.

Collaborative potential Past collaboration with XCR Diagnostics on COVID-19 testing demonstrates BIOLYPH’s capacity to scale and integrate with large test developers, signaling opportunities for co-development or contract manufacturing with other rapid-test players.

Regulatory readiness ISO 13485 and ISO 14971 accreditation indicate a mature quality and risk management framework, appealing to medical device and in vitro diagnostic (IVD) customers prioritizing compliant suppliers.

Compact team advantage With a lean employee base (11-50), BIOLYPH can offer agile partnerships, rapid iteration, and potentially lower overhead for pilot programs with startups and mid-sized diagnostic firms seeking outsourcing or technology transfer.

Revenue opportunity Reported revenue of 10–25 million places BIOLYPH as an established but scalable partner, suitable for tiered collaboration models ranging from technology licensing to contract manufacturing and private-label reagent systems.